vismodegib

To treat the disease, Roche's experimental medicine vismodegib, which is being developed together with U.S.-based Curis Inc., attempts to inhibit mutations in the Hedgehog signaling pathway, which regulates growth and development.

Roche Skin-Cancer Drug Meets Mid-Stage Trial Goals Goran Mijuk 2011

The fast approval of Zelboraf could be beaten with another skin-cancer drug from Roche, called vismodegib, which it developed with U.S. biotech Curis Inc.

For Some, Crisis Is Good Medicine Goran Mijuk 2011

The drug, known by its generic name vismodegib, will be sold under the brand name Erivedge and will be marketed in the U.S. by Genentech Inc. The drug will cost $7,500 for a monthly supply of once-a-day capsules.

New Type of Cancer Drug Gets Approval Jennifer Corbett Dooren 2012

The drug, a capsule called Erivedge (generically known as vismodegib), treats basal cell carcinoma that has metastasized (spread through the body), or that cannot be treated with surgery.

Yahoo! News: Business - Opinion 2012

Curis stands to receive an $8 million milestone payment if the FDA accepts the submission for review, and additional payments if the drug candidate, called vismodegib, is ultimately approved.

unknown title 2011

ZURICH— Roche Holding AG Monday said mid-stage trials of its experimental oral skin-cancer drug vismodegib showed the medicine to be successful in shrinking tumors in some patients.

Roche Skin-Cancer Drug Meets Mid-Stage Trial Goals Goran Mijuk 2011

Analysts said it was too early to provide sales estimates for vismodegib.

Roche Skin-Cancer Drug Meets Mid-Stage Trial Goals Goran Mijuk 2011

But Mr. Schwan said that recent drug trial data, including cancer treatments Zelboraf, vismodegib and pertuzumab, bode well for Roche's future, which, unlike many of its competitors, isn't under the immediate threat of patent losses.

Roche's Profit Drops 6%, But Lifts Outlook Goran Mijuk 2011

Roche Holding said mid-stage trials of its experimental oral skin cancer drug vismodegib showed the medicine to be successful in shrinking tumors in some patients.

Business Watch 2011

The Swiss group said a phase II study of vismodegib showed positive results in people with advanced basal-cell carcinoma as the tests met the primary endpoint of showing the drug shrank tumors in a pre-defined percentage of people.

Roche Skin-Cancer Drug Meets Mid-Stage Trial Goals Goran Mijuk 2011